The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades

Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015

(2017) M van der Meulen et al.   LEUKEMIA

Trends in primary central nervous system lymphoma incidence and survival in the U.S.

(2016) Meredith S. Shiels et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227

(2016) Jon Glass et al.   JOURNAL OF CLINICAL ONCOLOGY

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

(2016) K Fritsch et al.   LEUKEMIA

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013

(2016) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

(2016) Andrés J M Ferreri et al.   Lancet Haematology

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial

(2016) Gerald Illerhaus et al.   Lancet Haematology

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

(2015) A. Omuro et al.   BLOOD

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial

(2015) Antonio Omuro et al.   Lancet Haematology

The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma

(2013) Brian Patrick O'Neill et al.   AMERICAN JOURNAL OF HEMATOLOGY

Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

(2013) Patrick G. Morris et al.   JOURNAL OF CLINICAL ONCOLOGY

Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

(2013) James L. Rubenstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center

(2012) M. R. Welch et al.   NEURO-ONCOLOGY

Age, gender and racial differences in incidence and survival in primary CNS lymphoma

(2011) J L Villano et al.   BRITISH JOURNAL OF CANCER

Survival among patients with primary central nervous system lymphoma, 1973–2004

(2010) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

(2010) Eckhard Thiel et al.   LANCET ONCOLOGY